• Biodel Inc., of Danbury, Conn., entered a definitive securities purchase agreement with a group of institutional investors for the private placement of about 7.9 million shares, a portion of which will be nonvoting Series B preferred stock, and warrants for an additional 2.7 million shares. For each unit consisting of a share and warrant, the investors will pay $2.355, resulting in gross proceeds to Biodel of about $18.5 million. The exercise price of the five-year warrants is $2.66. The private placement is expected to close Wednesday. William Blair & Co. LLC acted as sole lead placement agent, with JMP Securities LLC as co-agent. Shares of Biodel (NASDAQ:BIOD) closed at $2.32 Friday.

• Coronado Biosciences Inc., of Burlington, Mass., priced its public offering of 5 million shares at $5 each. It also granted the underwriters a 30-day option to purchase up to 750,000 additional shares to cover overallotments. Coronado expects to receive about $23 million in net proceeds, which will be used to fund clinical trials, R&D and general operations. Oppenheimer & Co. Inc. and Roth Capital Partners are joint book-running managers, with National Securities Corp. as an underwriter. The offering is expected to close Wednesday. Shares of Coronado (NASDAQ:CNDO) closed at $5.30 Friday, down 6 cents.